INFARCT CELL THERAPY

Therapy after heart infarct: prevention of reperfusion injury and repair by stem cell transfer

Coordinatore	MEDIZINISCHE UNIVERSITAET WIEN    more  Organization address address: SPITALGASSE 23 city: WIEN postcode: 1090 contact info Titolo: Prof. Nome: Erhard Cognome: Hofer Email: send email Telefono: +43 1 4016033111 Fax: +43 1 40160933100
Nazionalità Coordinatore	Austria [AT]
Sito del progetto	http://www.infarctcelltherapy.eu/
Totale costo	3˙567˙100 €
EC contributo	2˙700˙000 €
Programma	FP7-HEALTH Specific Programme "Cooperation": Health
Code Call	FP7-HEALTH-2007-B
Funding Scheme	CP-FP
Anno di inizio	2009
Periodo (anno-mese-giorno)	2009-01-01   -   2012-06-30

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	MEDIZINISCHE UNIVERSITAET WIEN  Organization address address: SPITALGASSE 23 city: WIEN postcode: 1090 contact info Titolo: Prof. Nome: Erhard Cognome: Hofer Email: send email Telefono: +43 1 4016033111 Fax: +43 1 40160933100	AT (WIEN)	coordinator	464˙700.00
2	REGION HOVEDSTADEN  Organization address address: KONGENS VAENGE 2 city: HILLEROD postcode: 3400 contact info Titolo: Prof. Nome: Jens Cognome: Kastrup Email: send email Telefono: +45 35452817 Fax: +45 35452705	DK (HILLEROD)	participant	327˙000.00
3	KLINIKUM DER UNIVERSITAET ZU KOELN  Organization address address: Kerpener Strasse 62 city: KOELN postcode: 50937 contact info Titolo: Ms. Nome: Jutta Cognome: Landvogt Email: send email Telefono: +49 221 4785204 Fax: +49 221 4785543	DE (KOELN)	participant	312˙000.00
4	VIB  Organization address address: Rijvisschestraat 120 city: ZWIJNAARDE - GENT postcode: 9052 contact info Titolo: Prof. Nome: Peter Cognome: Carmeliet Email: send email Telefono: +32 16 345774 Fax: +32 16 345990	BE (ZWIJNAARDE - GENT)	participant	300˙000.00
5	BEN-GURION UNIVERSITY OF THE NEGEV  Organization address address: Office of the President - Main Campus city: BEER SHEVA postcode: 84105 contact info Titolo: Ms. Nome: Daphna Cognome: Tripto Email: send email Telefono: +972 8 6472425 Fax: +972 8 6472930	IL (BEER SHEVA)	participant	285˙000.00
6	TEL AVIV UNIVERSITY  Organization address address: RAMAT AVIV city: TEL AVIV postcode: 69978 contact info Titolo: Ms. Nome: Lea Cognome: Pais Email: send email Telefono: +972 3 640 8774 Fax: +972 3 640 9697	IL (TEL AVIV)	participant	282˙000.00
7	UNIVERSIDAD DE NAVARRA  Organization address address: CAMPUS UNIVERSITARIO EDIFICIO CENTRAL city: PAMPLONA postcode: 31080 contact info Titolo: Dr. Nome: Cristina Cognome: Patsouris Email: send email Telefono: +34 948 176748 Fax: +34 948 175223	ES (PAMPLONA)	participant	282˙000.00
8	EUROBIOSCIENCES GMBH  Organization address address: ALTENOYTHER STRASSE 10 city: FRIESOYTHE postcode: 26169 contact info Titolo: Dr. Nome: Werner Cognome: Luttmann Email: send email Telefono: +49 4491 93 87 804 Fax: +49 4491 93 87 805	DE (FRIESOYTHE)	participant	231˙300.00
9	VIVOCELL BIOSOLUTIONS GMBH & CO KG  Organization address address: STATTEGGER STRASSE 60 city: GRAZ postcode: 8045 contact info Titolo: Prof. Nome: Karl-Heinz Cognome: Preisegger Email: send email Telefono: +43 316 722866 10 Fax: +43 316 722866 99	AT (GRAZ)	participant	216˙000.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'A key problem in repair and functional regeneration following myocardial infarction is the inability of heart muscle tissue to regenerate itself and appropriate vascularization under conditions of increased strain caused by the reduced contractibility of the damaged heart. This frequently leads to continuous loss of functional cells, further increase of the infarct area and finally complete loss of heart function. We propose to explore possibilities for cell therapy using different procedures and sources of stem and progenitor cells. First, we will investigate factors stimulatory for stem/progenitor cell release from the bone marrow, their recruitment to the heart and the activation of resident heart stem cells. Second, we will evaluate adoptive transfer of stem/progenitor cells of different sources, from bone marrow, adult and cord blood, adipose tissue and heart tissue itself. The use of ex vivo cultured and differentiated cells including embryonic stem cells will be tested. Third, we will test genetic modification of these cells for improved differentiation, homing and tissue repair. Fourth, we will use a unique artificial scaffold material as a slow release device for factors and as a structural support material for providing the different cell preparations to the damaged areas. This scaffold will aso be used for tissue engineering in vitro followed by insertion of artficial tissue onto the infarct area. This project of high clinical importance is designed to further support the research and development needs of two SMEs, one is determined to become a supplier of growth factor cocktails for clinical stem cell culture, a second is based on the generation and supply of stem cells for clinical use. It will evaluate whether induction of repair by factors, adoptive transfer of stem/progenitor cells or engineered tissue has benefit for heart regeneration and has potential to become a future clinical standard therapy.'